We are live on
!
Find out more
HMC
Harvard Management Company Portfolio holdings
AUM
$1.82B
1-Year Est. Return
26.23%
This Fund
S&P 500
This Quarter
Est. Return
-20.88%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$991M
AUM Growth
-$74.7M
(-7%)
Cap. Flow
+$164M
Cap. Flow
% of AUM
16.57%
Top 10 Holdings %
Top 10 Hldgs %
82.31%
Holding
48
New
2
Increased
4
Reduced
–
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$215M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$70.8M |
| 3 |
PureCycle Technologies
PCT
|
+$10.4M |
| 4 |
Grab
GRAB
|
+$8.52M |
| 5 |
VIGL
Vigil Neuroscience
VIGL
|
+$3.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$138M |
| 2 |
ASML
ASML
|
+$7.19M |
| 3 |
DADA
Dada Nexus
DADA
|
+$531K |
| 4 |
Surrozen Inc Warrant
SRZNW
|
+$125K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 52.08% |
| 2 | Healthcare | 19.11% |
| 3 | Consumer Discretionary | 15.88% |
| 4 | Technology | 8.04% |
| 5 | Industrials | 2.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Meta Platforms (Facebook)
META
$1.51T
| $274M | 27.63% |
1,231,019
+858,894
| +231% | +$215M |
|
|
2
Alphabet (Google) Class A
GOOGL
$3.91T
| $242M | 24.45% |
1,741,740
+521,420
| +43% | +$70.8M |
|
|
LNW
3
DELISTED
Light & Wonder
LNW
| $157M | 15.88% |
2,678,571
| – | – |
|
4
AbCellera Biologics
ABCL
$1.62B
| $40M | 4.04% |
4,105,095
| – | – |
|
|
EQRX
5
DELISTED
EQRx, Inc. Common Stock
EQRX
| $21.7M | 2.19% |
5,262,161
| – | – |
|
|
6
PureCycle Technologies
PCT
$1.17B
| $20M | 2.02% |
2,498,170
+1,428,570
| +134% | +$10.4M |
|
7
Revolution Medicines
RVMD
$40.2B
| $17.1M | 1.73% |
670,382
| – | – |
|
8
Relay Therapeutics
RLAY
$4.02B
| $16.2M | 1.63% |
541,124
| – | – |
|
9
10x Genomics
TXG
$5.87B
| $14.2M | 1.43% |
186,143
| – | – |
|
|
10
Grab
GRAB
$13.5B
| $12.9M | 1.3% |
3,684,960
+1,684,960
| +84% | +$8.52M |
|
11
Recursion Pharmaceuticals
RXRX
$1.57B
| $10.8M | 1.09% |
1,509,254
| – | – |
|
|
MEKA
12
DELISTED
MELI Kaszek Pioneer Corp Class A Ordinary Shares
MEKA
| $10.3M | 1.04% |
1,000,000
| – | – |
|
13
Fulcrum Therapeutics
FULC
$248M
| $9.71M | 0.98% |
410,714
| – | – |
|
14
Rocket Lab Corp
RKLB
$39.9B
| $8.05M | 0.81% |
1,000,000
| – | – |
|
15
Affirm
AFRM
$23.5B
| $8.03M | 0.81% |
173,560
| – | – |
|
16
Micron Technology
MU
$1.04T
| $8M | 0.81% |
102,684
| – | – |
|
17
Praxis Precision Medicines
PRAX
$9.07B
| $7.95M | 0.8% |
51,901
| – | – |
|
18
Tenaya Therapeutics
TNYA
$168M
| $7.93M | 0.8% |
673,270
| – | – |
|
19
Intel
INTC
$466B
| $7.47M | 0.75% |
150,806
| – | – |
|
20
NVIDIA
NVDA
$5.01T
| $7.18M | 0.72% |
263,150
| – | – |
|
21
Analog Devices
ADI
$181B
| $6.89M | 0.7% |
41,739
| – | – |
|
22
Lam Research
LRCX
$382B
| $6.73M | 0.68% |
125,210
| – | – |
|
23
TSMC
TSM
$2.09T
| $6.72M | 0.68% |
64,443
| – | – |
|
24
Applied Materials
AMAT
$426B
| $6.66M | 0.67% |
50,553
| – | – |
|
25
Advanced Micro Devices
AMD
$851B
| $5.97M | 0.6% |
54,610
| – | – |
|
Similar funds
DWT
MCC
ST
DE
SI
WIC
GC
RHJA
Harvard Management Company's Q1 2022 Portfolio in Review
As of Q1 2022, Harvard Management Company held 48 positions worth $991M, down 7% from $1.07B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Harvard Management Company deployed $164M of net new capital in Q1 2022, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Vigil Neuroscience: 289,460 shares worth $2.04M.
By sector, the portfolio is most concentrated in Communication Services at 52% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the most notable exit was Royalty Pharma, an estimated $138M sold.
- Harvard Management Company's largest Q1 2022 buy was Vigil Neuroscience: 289,460 shares worth $2.04M.
- Harvard Management Company added most to Meta Platforms (Facebook) in Q1 2022, an estimated $215M increase.
- Harvard Management Company fully exited Royalty Pharma in Q1 2022, selling an estimated $138M.
- Harvard Management Company's ten largest holdings make up 82% of its $991M portfolio in Q1 2022.
- Harvard Management Company opened 2 new positions and closed 4 in Q1 2022.
- Harvard Management Company's portfolio value fell 7% quarter-over-quarter to $991M.
Based on Harvard Management Company's 13F filing for Q1 2022, filed 13 May 2022.